Between 1996 and 2004, a total of 708 patients were enrolled in the acute myeloid leukaemia (AML) '96 and '02 studies of the East German Study Group (OSHO). Of these, 138 patients (19.5%) had unfavourable cytogenetics defined as complex karyotype, del (5q)/-5, del (7q)/-7, abn (3q26) and abn (11q23). In all, 77 (56%) achieved complete remission 1 (CR1) after induction chemotherapy and were eligible for haematopoietic cell transplantation (HCT). HCT was performed after a median of two cycles of consolidation chemotherapy (CT) in the AML '96 and one cycle in the AML '02 study (P ¼ 0.03). After a median follow-up of 19 months, overall survival (OS) at two years was significantly better in the donor group (52 ± 9%) versus the no-donor group (24±8%; P ¼ 0.005). Differences in outcomes were mainly because of a lower relapse incidence in patients after HCT (39±11%) compared with a higher relapse incidence in patients undergoing CT (77 ± 10%; P ¼ 0.0005). Treatment-related mortality was low and not statistically significantly different between the two treatment groups (15 ± 7 and 5 ± 5% for HCT and chemotherapy, respectively; P ¼ 0.49).We conclude that early HCT from related or unrelated donors led to significantly better OS and leukaemia-free survival compared with chemotherapy in patients with unfavourable karyotype.
Introduction
Allogeneic haematopoietic stem cell transplantation (HCT) after myeloablative conditioning has been established as an important treatment strategy to reduce the relapse risk of patients with acute myeloid leukaemia (AML). 1 However, it is also known that allogeneic HCT is associated with an increase in treatmentrelated mortality (TRM), which adversely affects the outcome. 2 Cytogenetic analysis has enabled to partially unravel the heterogeneity of AML, such that three cytogenetic prognostic profiles (favourable, intermediate and unfavourable) are currently in common use. 3 Although randomized controlled trials are the gold standard for the evaluation of treatment efficacy, they have not been proven feasible in the assessment of the role of HCT in haematological malignancy. Genetic randomization offers an alternative strategy, which has been adopted in a number of recent studies. [4] [5] [6] [7] [8] [9] [10] Three such donor versus no-donor studies have recently suggested that HCT results in superior leukaemia-free survival (LFS) in patients with AML in complete remission 1 (CR1). [4] [5] [6] An EORTC/GIMEMA study showed that patients aged o46 years with AML in CR1 with bad-risk cytogenetics, who were assigned to allogeneic HCT from related donors, had a significantly better outcome than those who were assigned to autologous-HCT. 6 In a more recent study, the HOVON-SAKK group evaluated their results together with those of the earlier (MRC, BGMT and EORTC) studies in a meta-analysis. Results showed a significant benefit of 10% in overall survival (OS) at 4 years by donor availability for all patients with AML in CR1, who did not have a favourable cytogenetic profile. 10 Here we address the question of whether the use of allogeneic HCT in patients with poor risk AML has a favourable impact on DFS and OS. The outcomes of patients with poor risk AML in CR1 with a matched related or unrelated donor HCT has been compared with the outcomes of those who lacked a donor and received chemotherapy/autologous HCT. The analysis is based on patients enrolled in two successive AML studies conducted by the OSHO.
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Materials and methods
Patient characteristics
Between July 1997 and August 2006, 708 patients below the age of 60 years with newly diagnosed, de novo and secondary AML were enrolled into the prospectively randomized controlled AML '96 and AML '02 studies. Only patients with FAB M3 or APL were excluded. Patients were excluded from the study if they had decompensated liver disease, a corrected pulmonary-diffusing capacity of o35%, a cardiac ejection fraction of o30%, a Karnofsky performance status of o10% or serologic evidence of infection with the human immunodeficiency virus. In all, 76 (20%) patients in the OSHO AML '96 and 62 (18%) in the OSHO AML '02 trial had unfavourable karyotype, with 38 (50%) and 39 (63%) of them achieving CR1, respectively ( Figure 1 ). Continuous CR1 before HCT or consolidation chemotherapy (CT) was observed in 23 and 37 patients, respectively. The median time from last chemotherapy to HCT/CT was 73 (range, 10-292) days and 68 (range, 33-125) days in the HCT and CT groups, respectively (P ¼ 0.28; Table 1 ). Consistent with the aims of the AML '02 study, HCT was performed earlier following CR than in the AML '96 study after reaching CR.
Treatment protocols
The AML '96 study addressed the question of the optimal cytosine arabinoside infusion rate for induction chemotherapy and the use of related or unrelated HCT in high-risk patients after two consolidation therapies. . This cycle was repeated once if no CR was achieved. In the event of CR, patients received two consolidation cycles and were assigned either to a third CT or autologous HCT, if no related or unrelated donor was available, or to HCT from related or unrelated donor (Figure 1 ). Analyses on OS and LFS in the AML '96 study showed no differences between the two arms. (Niederwieser D et al., manuscript in preparation).
The AML '02 study aimed at improving CR rate by testing two different chemotherapy regimens in patients not achieving CR after one induction cycle and at improving survival in patients with unfavourable cytogenetics performing HCT early in CR1. One of the induction arms of the AML '96 study consisting of idarubicin and AraC (idarubicin dose 12 mg/m 2 on days 1-3 in combination with 2 Â 1 g/m 2 over 3 h i.v. on days 1, 3, 5 and 7) was used in the AML '02 study. Patients in CR with intermediate and favourable cytogenetics were randomly assigned to treatment with one or two cycles of chemotherapy followed by autologous or allogeneic HCT. In contrast, patients with unfavourable cytogenetics were allocated to allogeneic HCT as soon as possible if a suitable related or unrelated donor was available ( Figure 1 ). Complex abnormalities (that is, defined as at least three unrelated cytogenetic abnormalities), such as À5q/ À5, À7q/À7, abn (3q26) and abn(11q23), were considered unfavourable cytogenetics.
Approval for both studies was obtained from the University of Leipzig Medical Ethical Committee as well as the institutional review boards of all the participating centres in both multicentre studies. Written informed consent was obtained from all participating patients.
Human leukocyte antigen typing and matching
All related and unrelated donor-recipient pairs were selected on the basis of serologic matching for human leukocyte antigen (HLA) class I and molecular matching for HLA-DRB1. Three unrelated pairs had one HLA-A or one HLA-B antigen mismatch. No. of consolidations; median (range) Abbreviations: AML, acute myeloid leukaemia; CR, complete remission; CT, consolidation chemotherapy; HCT, haematopoietic cell transplantation.
Allogeneic HCT in high-risk AML N Basara et al In addition, retrospective allele level typing was performed in the majority of donor-recipient pairs for HLA-A, -B, -C, -DQB1 and -DPB1 alleles using direct automated fluorescent methods, as described.
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Transplant procedure
All patients were conditioned with a conventional preparative regimen consisting of 12 Gy total body irradiation delivered at 0.07-0.20 Gy/min from day À6 to À4 using linear accelerators followed by cyclophosphamide 60 mg per kg body weight on days À3 and À2. Granulocyte colony-stimulating factor mobilization and harvest of peripheral blood mononuclear cells (G-PBMC), infusion of donor haematopoietic cells and antimicrobial prophylaxis were performed, as earlier reported. [14] [15] [16] All patients received cyclosporine A (CsA) from day À1 and long-course methotrexate (MTX) for graft versus host disease (GvHD) prophylaxis. Cyclosporine A was applied at a dose of 5 mg/kg divided into two doses over 4 h and according to daily determined plasma levels (200 ng/ml). Methotrexate was given i.v. at a dose of 15 mg i.v. on days þ 1, þ 3, þ 6 and þ 11. All patients received leukovorin 15 mg i.v. on days þ 2, þ 4, þ 7 and þ 12 at 24 h after MTX. In unrelated transplants, ATG (ATG-S, Fresenius, Bad Homburg, Germany) was given in a total dose of 45 mg per kg body weight over 6 h from day À5 to À3 with premedication (250 mg prednisone i.v.). Toxicities were determined using the National Cancer Institute Common Toxicity Criteria, Version 2.0. The local investigators performed GvHD grading using standard criteria. 17, 18 Engraftment was defined as the first of 3 consecutive days when the patient's neutrophil counts exceeded 0.5 Â 10 9 /l.
End points and statistical methods
Data were analysed as of August 2006. Overall survival (OS) and LFS were estimated on an intent-to-treat basis by the Kaplan-Meier method from the date of achieving CR1. The event for OS was death because of whatever cause and patients were censored at the date of last contact if alive. Patients who died without evidence of relapse and progression were considered to have died of non-relapse causes. Comparison of these data was based on results of log rank statistics. Risk factors were analysed using proportional hazards regression models, treating death before acute GvHD, rejection and relapse as competing events. The multivariate models were constructed in a stepwise manner. All P-values were derived from likelihood ratio statistics and were two-sided. The impact of variables such as age, de novo or secondary high-risk cytogenetic AML, the number of courses before achieving CR1, the time interval between achieving CR1 to HCT or CT and the presence of complex karyotypes in comparison with the other unfavourable cytogenetic alterations and treatment (CT vs HCT) were analysed in the univariate analysis. The significant factors were subsequently tested in the multivariate analysis.
Results
Donor availability and consolidation treatment applied
Between 1 October 1997 and 1 August 2006, 708 patients were included in two consecutive AML '96 and AML '02 studies of the OSHO. One hundred and thirty-eight patients were found to have an unfavourable karyotype and were identified as poor-risk AML. Of these, 77 patients (56%) achieved CR and were allocated to related or unrelated HCT (n ¼ 47), or to chemotherapy/autologous HCT (n ¼ 30). In the further treatment course, 17 patients died from disease relapse or from toxicity during or after the first consolidation, so that a total of 60 patients were in CR1 before CT or HCT. Finally, HCT from HLAidentical sibling donor was performed in 13 patients (22%) and HCT from unrelated donors was performed in 21 patients (35%). Furthermore, conventional chemotherapy was given to 21 patients (35%) and autologous HCT to 5 (8%) of the 60 patients lacking a suitable donor. The median follow-up of patients following diagnosis was 19 (range 4-94) months calculated from CR. Patient characteristics of the donor (HCT) and no-donor (CT) groups are presented in Table 1 . The two groups are comparable with respect to type of AML (de novo or secondary) and time interval from CR to HCT or CT. As expected, the numbers of consolidation courses before HCT were higher in patients treated in the AML '96 study amounting to median 1 (range 1-2) for patients with related HCT and median 2 (range 0-3) for unrelated HCT. In the AML '02, HCT was performed after median 0 (range 0-1) consolidation therapies for related HCT and after median 1 (range 0-3) consolidation courses for unrelated HCT (number of consolidation courses AML '96 vs '02 P ¼ 0.03, Table 1 ).
Survival, relapse incidence, non-relapse mortality, engraftment and graft failure
All patients engrafted at a median of 16 (range 10-26) days after HCT. At a median follow-up of 21 (range 11-62) months, 15 (range 4-61) months and 12 (range 4-94) months, 22 of the 34 patients after matched related or unrelated HCT and 7 of the 30 patients after CT/autologous HCT were alive. Of these, 20 and 6 patients, respectively, were in continuous CR1. Overall survival and LFS were determined in an intention-to-treat analysis evaluating 77 patients at CR1. As shown in Figures 2a and b , patients with a donor had a better OS and LFS than patients without a donor (OS 52 ± 9 vs 24 ± 8% at 2 years, P ¼ 0.005; LFS 42 ± 8 vs 19 ± 8% at 2 years, P ¼ 0.009). Among the factors detected in the univariate analysis, treatment (HCT vs CT/autologous HCT; P ¼ 0.002) remained significant and age showed a trend (P ¼ 0.09) in the multivariate analysis. Analysis for OS and LFS as treated showed similar results. Overall survival was best for HCT 60 ± 10%, followed by CT 22 ± 11% (Po0.001; Figure 3a) . In a multivariate analysis, the factors associated with better OS and lower risk of relapse were younger age (P ¼ 0.008) and HCT (P ¼ 0.001). Similarly, LFS was significantly better in the HCT (52 ± 10%) compared with the chemotherapy/autologous HCT group (22±9%, P ¼ 0.002; Figure 3b ). The main reasons for these differences were decreased relapse incidence after HCT (39±11%) compared with the chemotherapy/autologous HCT group (77 ± 10%, Po0.0005; Figure 4 ) in the absence of any difference in nonrelapse mortality between the three treatment groups (15 ± 7 and 5±5% for HCT and CT/autologous HCT, respectively, P ¼ 0.49; Figure 5 ).
Discussion
The role of HCT for AML in CR1 has progressed from early reports on syngeneic marrow transplantation 19 to the extensive body of data now available [4] [5] [6] 10, 11 providing evidence for a superior LFS in the group assigned to HCT. However, none of the studies to date has been able to show a benefit in OS in adult AML undergoing HCT, which has been an issue of extensive debate in the haematology community in recent years. 8, 20, 21 A Allogeneic HCT in high-risk AML N Basara et al possible explanation for the lack of a significant difference in OS of patients with AML treated with chemotherapy, autologous SCT or allogeneic SCT could be the relatively low number of AML cases combined with the pathobiological heterogeneity of the disease. Subgrouping of AML according to risk categories leads to smaller groups and reduces the power of the statistical analysis. 7, 9 The OSHO cooperative group has run two successive trials in adult AML patients o60 years in which HCT has been the standard treatment for all patients achieving CR for whom an HLA-identical related donor is available and in all high-risk AML patients who have an HLA-identical related or unrelated donor. The aim of the OSHO '02 study was to perform an allogeneic HCT in high-risk AML patients as soon as possible after achieving CR1. The present study shows that 95% of highrisk AML patients achieving CR1 were indeed evaluated for transplant, with 72% of patients having undergone allogeneic HCT in AML '02. This number of HCTs performed far exceeds that in the AML '96 study (41%), the main reason being the lower relapse rate and mortality following consolidation therapy even before HCT or CT. In fact, whereas 15 patients in CR either relapsed or died of toxicity of consolidation therapy toxicity before transplant or consolidation in the AML '96 study, only two patients relapsed before HCT or CT in the AML '02 study. In contrast to the EORTC/GIMEMA study, in which patients with AML in CR1 aged o46 years with poor-risk cytogenetics were assigned to allogeneic HCT from related donors or autologous HCT, unrelated HCT was a major component in this study and the comparator chemotherapy and autologous HCT were used instead of autologous HCT. 6 Although data are based on small groups of patients drawn from two different study cohorts with a short median follow-up time, this is the first study showing that both LFS and OS were significantly better in allogeneic HCT including unrelated HCT compared with CT/autologous HCT in patients with unfavourable cytogenetics (Figures 2a and b) . Years from CR1 Allogeneic HCT in high-risk AML N Basara et al
The significant difference in 2-year LFS and OS was due to the lower relapse incidence. Indeed, a strong reduction in relapse incidence was observed in the HCT compared with the CT/ autologous HCT patients ( Figure 4 ). This is consistent with other studies [4] [5] [6] showing a significant increase in LFS and lower relapse incidence in the donor group, coupled with a higher TRM, which adversely affects OS in the donor group.
A very important result of our study was the fact that the TRM of 15 ± 7% in the HCT group at 2 years (15 ± 9 and 14 ± 10% for related and unrelated HCT, respectively) was not significantly different from that of the CT group (5 ± 5%, P ¼ 0.49). The TRM in our study is also low compared with previously published data reporting TRM in matched related HCT of 23%, 4 17% 6 and 25%, 10 all of which were statistically different from the CT/autologous HCT group. Similarly, among patients with AML in CR1 (median age 34 years) undergoing non-T-cell depleted, matched sibling HCT following standard Cy/TBI or Bu/Cy conditioning, TRM was found to be 23-25% at 1 year. 22 The TRM observed in our study in matched and partially matched unrelated HCT (12% at 2 years) is also much lower than that recently reported from 236 consecutive prospectively analysed patients. 23 Among patients with acute leukaemia, CML and MDS with a median age of 37 years undergoing sibling or HLA-allele matched (10/10) unrelated HCT following TBI/Cy conditioning, TRM was 29.2 and 23.9%, respectively. The low TRM in unrelated HCT is consistent with our recently published data following reduced intensity conditioning (11%), 16 indicating the necessity for better infection prevention and careful, routine control of immune reconstitution as performed within the OSHO study group. Strict isolation during aplasia, preemptive cytomegalovirus therapy, prophylactic treatment for pneumocystis carinii and prophylactic treatment for patients at risk for toxoplasmosis might be the reason for low TRM in our series. This may contribute to the difference in OS in our group of patients compared with those earlier published. [4] [5] [6] It may also be relevant that the analysis in our study concentrates on a highrisk group of patients with unfavourable karyotype rather than on all AML patients.
The incidence of AML patients with unfavourable karyotype was 20 and 18% in the OSHO AML '96 and AML '02 studies, respectively, which is similar to other reports: 30% Slovak et al.
24 21% Burnett et al. 25 21% Suciu et al. 6 It has been generally accepted that cytogenetic analysis performed at diagnosis is the single most valuable prognostic factor for the response to induction therapy in AML. 3 However, discrepant results have been obtained regarding relapse risk in cytogenetic defined subgroups of AML. 5, 6, 24 The estimated 4-year LFS rate in a subgroup of unfavourable cytogenetic AML patients was significantly better in the donor than in the no-donor group (43.4 vs 18.4% with relapse rates of 38.2 vs 75.9% and TRM of 18.4 vs 5.7%). 6 In the unfavourable group of a SWOG analysis, 24 heterogeneity among the three post-remission treatment arms (allogenic HCT, autologous HCT and chemotherapy) was not statistically significant, although patients seemed to benefit in the allogenic HCT arm (P ¼ 0.043 compared with auto plus chemotherapy arms). This was in contrast to our study showing differences in OS, LFS and relapse incidence between HCT (including unrelated HCT) and CT/autologous HCT.
In conclusion, our policy of performing allogeneic SCT from related or unrelated donor in adult patients with AML early after achieving CR has been effective in patients with unfavourable cytogenetics. Further, post-transplant strategies might improve the current results especially in terms of relapse incidence.
